Nuclear Factor- B and Tumor-Associated Macrophages
نویسندگان
چکیده
منابع مشابه
Nuclear Factor-κB and Tumor-Associated Macrophages
Authors' A Marseille-L Correspon Parc Scien 33-0-4-91univ-mrs.fr
متن کاملRegulation of Fas (CD95)-induced apoptosis by nuclear factor- B and tumor necrosis factor- in macrophages
BIN LU,1 LIYING WANG,2 DJORDJE MEDAN,1 DAVID TOLEDO,1 CHUANSHU HUANG,3 FEI CHEN,2 XIANGLIN SHI,2 AND YON ROJANASAKUL1 1Department of Basic Pharmaceutical Sciences, Health Sciences Center, West Virginia University, Morgantown 26506; 2Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505; and 3Nelson Institute of Environmental M...
متن کاملP157: Periostin Recruits Tumor Associated Macrophages in Glioblastoma Multiform
Glioblastoma multiform (GBM) is the most common and lethal type of primary brain tumors with high rates of morbidity and mortality. Treatment options are limited and ineffective in most of the cases. Epidemiological studies have shown a link between inflammation and glioma genesis. In addition, at the molecular level, pro-inflammatory cytokines released from activated microglia can increa...
متن کاملp50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance.
Tumor-associated macrophages (TAM) are a major inflammatory infiltrate in tumors and a major component of the protumor function of inflammation. TAM in established tumors generally have an M2 phenotype with defective production of interleukin-12 (IL-12) and high IL-10. Here, we report that defective responsiveness of TAM from a murine fibrosarcoma and human ovarian carcinoma to M1 activation si...
متن کاملTumor-associated macrophages in diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma and affected patients’ outcomes vary from the extremes of cure in the majority of patients to the dismal prognosis of primary refractory and, to a lesser extent, relapsed disease that occur in 30-40% of cases. The understanding of tumor and host factors that contribute to treatment failure is, therefore, a critical hur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2010
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-09-1015